Statistiche di base
| LEI | 5493005RDYAV26LAQ930 |
| CIK | 1538210 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NexImmune, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. |
|
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. |
|
| August 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. |
|
| August 27, 2024 |
As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No. |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NEX |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 11, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 21, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as perm |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 11, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| June 11, 2024 |
CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF NEXIMMUNE, INC. Exhibit 3.2 CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF NEXIMMUNE, INC. NexImmune, Inc., a Delaware corporation (“Company”), does hereby certify that the Board of Directors of the Company (“Board”) adopted the following resolution: RESOLVED, pursuant to authority conferred by the Sixth Amended and Restated Certificate of Incorporation of the Company, the Board designates, creates and |
|
| June 11, 2024 |
AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF NEXIMMUNE, INC. Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF NEXIMMUNE, INC. This Amendment (this “Amendment”) to the Amended and Restated Bylaws (the “Bylaws”) of NexImmune, Inc., a Delaware corporation (the “Company”), is effective as of June 7, 2024 and is made pursuant to Article Seventh of the Sixth Amended and Restated Certificate of Incorporation, as amended, of the Company. 1. Section 4 of |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NE |
|
| May 15, 2024 |
SEC FILE NUMBER 001-40045 CUSIP NUMBER 65344D 208 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| April 16, 2024 |
NexImmune, Inc. Clawback Policy NEXIMMUNE, INC. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of NexImmune, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this policy w |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 29, 2024 |
SEC FILE NUMBER 001-40045 CUSIP NUMBER 65344D 208 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 5, 2024 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT NEXIMMUNE, INC. Warrant Shares: Issue Date: , 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| February 5, 2024 |
Form of Placement Agent Warrant. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 5, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 2, 2024, between NexImmune, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| February 5, 2024 |
NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules GAITHERSBURG, Md. – February 2, 2024 – NexImmune, Inc. (Nasdaq: NEXI) (the “Company”), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune a |
|
| February 5, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 5, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263399 PROSPECTUS SUPPLEMENT (To Prospectus dated March 16, 2022) NexImmune, Inc. 117,000 Shares of Common Stock Pre-Funded Warrants to Purchase 187,731 Shares of Common Stock Up to 187,731 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering 117,000 shares of our common stock, par value $0.0001 per share, |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| December 22, 2023 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| November 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| November 20, 2023 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-4004 |
|
| November 15, 2023 |
NT 10-Q SEC FILE NUMBER 001-40045 CUSIP NUMBER 65344D 208 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 18, 2023 |
Exhibit 99.1 NexImmune Announces 1-for-25 Reverse Stock Split October 18, 2023 GAITHERSBURG, Md. – Oct. 18, 2023 – NexImmune, Inc. (Nasdaq: NEXI) (the “Company”) a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells in oncology, autoimmune and infectious diseases, today announced |
|
| October 18, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. NexImmune, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: FIRST: The name of the corporation is NexImmune, Inc. (the “Corporation”). SECOND: The date of filing of the original Certificate of |
|
| September 25, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ☒ Definitive Proxy Stat |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| September 13, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NEX |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 10, 2023 |
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates •NEXI-001 data presented at ASCO 2023 demonstrates proof-of-concept in patients with relapsed AML after allogeneic hematopoietic cell transplantation (HCT) and refractory to additional chemotherapy or salvage treatments; one patient continues to show no evidence of disease at nine months •Preclinical |
|
| June 5, 2023 |
EX-99.1 Exhibit 99.1 NexImmune Presents Initial Positive Data in the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting - Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 tre |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 18, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 15, 2023 |
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates Exhibit 99.1 NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates •Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication •NEXI-001 Phase I data to be presented at ASCO 2023 in June GAITHERSBURG, Md., May 15, 2023 - NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orches |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NE |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 7, 2023 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-263399 PROSPECTUS SUPPLEMENT (To Prospectus dated March 16, 2022 as supplemented by the Prospectus Supplement dated June 17, 2022) Up to $4,150,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus supplement, dated June 17, 2022, filed with the Securities and Exchange Commission as a part of our r |
|
| April 7, 2023 |
NEXI / Neximmune Inc / BARER SOL J - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NEXIMMUNE, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) c/o NexImmune, Inc. 9119 Gaither Road Gaithersburg, Maryland 20878 (Name, Address and Telephone Number of Person Auth |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only [ ] Definitive Proxy Statement [x] |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only [X] Definitive Proxy Statement [ ] |
|
| March 28, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Neximmune, Inc. |
|
| March 28, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 28, 2023 |
NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Exhibit 99.1 NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates •Company has initiated Pre-IND discussions with the FDA for its first AIM INJ indication •NEXI-001 completed enrollment in its final safety cohorts and all patients have been dosed, Company continues to follow patients and will announce data at or around an upcoming scientific conferenc |
|
| March 28, 2023 |
Powers of Attorney (included on signature page to this Registration Statement) As filed with the Securities and Exchange Commission on March 28, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| March 28, 2023 |
Agreement, by and between the Company and Jerome Zeldis, M.D., Ph.D., dated CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”), effective as of April 1, 2023 (the “Effective Date”), is entered by and between NexImmune, Inc. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 15, 2023 |
NEXI / NexImmune, Inc. / ArrowMark Colorado Holdings LLC Passive Investment SC 13G/A 1 arrowmark-nexi123122a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* NEXIMMUNE, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65344D109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 13, 2023 |
NEXI / NexImmune, Inc. / BARER SOL J - SC 13G/A Passive Investment SC 13G/A 1 d437879dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEXIMMUNE, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 13, 2023 |
NEXI / NexImmune, Inc. / B&S NexImmune Holdco LLC - SC 13G/A Passive Investment SC 13G/A 1 d428779dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEXIMMUNE, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 13, 2023 |
NEXI / NexImmune, Inc. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A 1 d460748dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 1) NEXIMMUNE, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-4004 |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2022 |
NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update Exhibit 99.1 NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update •Company announces a strategic shift to focus on advancing its AIM Direct Injection (AIM INJ) platform and potential product candidates in oncology and autoimmune diseases •Initiating a corporate resource reallocation to advance the AIM INJ platform, reduce operating expenses and extend cash runway t |
|
| October 28, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NEX |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 15, 2022 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this ?Amendment?) is dated as of August 11, 2022 and is entered into by and between Mathias Oelke (the ?Employee?) and NexImmune, Inc. |
|
| August 15, 2022 |
Exhibit 99.1 NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers ?Received U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug (IND) submission for NEXI-003, the Company?s first solid tumor product candidate for the treatment of HPV-related cancers ?Plans to report additional pre |
|
| July 14, 2022 |
NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of Exhibit 99.1 NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers ? First IND for NexImmune?s AIM nanoparticle platform in solid tumors ? IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-related ca |
|
| July 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 17, 2022 |
EX-1.1 2 d340163dex11.htm EX-1.1 Exhibit 1.1 NEXIMMUNE, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement June 17, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 BTIG, LLC 600 Montgomery Street San Francisco, CA 94111 Ladies and Gentlemen: NexImmune, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agr |
|
| June 17, 2022 |
Up to $50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-263399 PROSPECTUS SUPPLEMENT (To Prospectus dated March 16, 2022) Up to $50,000,000 Common Stock We have entered into a Controlled Equity OfferingSM sales agreement, or Sales Agreement, with Cantor Fitzgerald & Co. and BTIG, LLC (each an ?Agent and collectively the ?Agents?), dated June 17, 2022, relating to the offer and sale |
|
| June 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 NEXIMMUNE, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-40045 42-2518457 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2022 |
Joint Research Agreement, by and between Zephyr AI, Inc. and NexImmune, Inc., dated March 16, 2022 JOINT RESEARCH AGREEMENT This JOINT Research Agreement (?Agreement?) is entered into on March 16, 2022 (the ?Effective Date?) by and between NexImmune, Inc. |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NE |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 12, 2022 |
Employment Agreement, by and between the Registrant and Mathias Oelke, date April 5, 2022 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of April 5, 2022, effective as of April 5, 2022 (the ?Effective Date?) by and between Mathias Oelke (?Employee?) and NexImmune, Inc. |
|
| May 12, 2022 |
NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates Exhibit 99.1 NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates ?Clinical data updates for the Company?s two lead product candidates in Phase 1/2 clinical trials expected in 2H22 ?Investigational New Drug (IND) submission for NEXI-003, the Company?s first product for solid tumors, planned for 1H22 ?Plans to report additional preclinical and IND enabling data for t |
|
| May 10, 2022 |
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors Exhibit 99.1 NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors GAITHERSBURG, MD ? May 10, 2022 ? NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Leena Gandhi, M.D. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only [ ] Definitive Proxy Statement [x] |
|
| May 3, 2022 |
DEF 14A 1 neximmuneinc-proxy.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission |
|
| April 14, 2022 |
Exhibit 99.1 NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology GAITHERSBURG, MD ? April 14, 2022, NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted |
|
| April 14, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 17, 2022 |
Exhibit 99.1 NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation GAITHERSBURG, MD ? March 17, 2022 ? NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology. Combining Zephyr?s proprietary artificial intel |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 14, 2022 |
NEXIMMUNE, INC. 9119 Gaither Road Gaithersburg, MD 20877 CORRESP 1 filename1.htm NEXIMMUNE, INC. 9119 Gaither Road Gaithersburg, MD 20877 March 14, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart RE: NexImmmune, Inc. Registration Statement on Form S-3 Filed March 9, 2022 File No. 333-263399 Acceleration Request Dear Ms. Ansart: With respec |
|
| March 9, 2022 |
As filed with the Securities and Exchange Commission on March 9, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 9, 2022 |
Exhibit 99.1 NexImmune Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates ?Clinical data updates for the Company?s two lead product candidates in Phase 1/2 clinical trials expected in 2H22 ?Investigational New Drug (IND) submission for NEXI-003, the Company?s first product for solid tumors, planned for 1H22 ?Plans to report additional preclinical and IND en |
|
| March 9, 2022 |
Form of Subordinated Indenture Exhibit 4.6 NEXIMMUNE, INC. Issuer AND [?] Trustee INDENTURE Dated as of [?] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13 (a) 311(b). 7.13 (b) 311(c). Inapplicable 312(a) 5.02 (a) 312(b). 5.02 (b) 312(c). 5.02 (c) 313(a). 5.04 (a) 313(b). 5.04 (a) 313(c |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Neximmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (1) Fees to Be Paid Equity Comm |
|
| March 9, 2022 |
Exhibit 4.5 NEXIMMUNE, INC. Issuer AND [?] Trustee INDENTURE Dated as of [?] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) 5. |
|
| March 9, 2022 |
Employment Agreement, by and between the Company and Kristi Jones, dated EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is entered into as of March 8, 2022, effective as of February 15, 2022 (the ?Effective Date?) by and between Kristi Jones (?Employee?) and NexImmune, Inc. |
|
| March 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Neximmune, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 |
|
| March 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 9, 2022 |
As filed with the Securities and Exchange Commission on March 9, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 9, 2022 Registration No. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| February 22, 2022 |
NEXI / NexImmune, Inc. / Brady Louise F. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NexImmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65344D109 (CUSIP Number) February 11, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 18, 2022 |
NEXI / NexImmune, Inc. / Long Robert E. Jr. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NexImmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65344D109 (CUSIP Number) February 11, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2022 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| February 17, 2022 |
Separation Agreement, dated February 12, 2022 Exhibit 10.1 February 12, 2022 Mr. Scott Carmer Re: Separation Agreement Dear Scott: You are resigning as the Chief Executive Officer of NexImmune, Inc. (the ?Company?). The purpose of this letter agreement (this ?Agreement?) is to set forth the terms of your resignation from the Company. 1. Separation of Employment. Your employment with Company will end effective as of February 12, 2022 (the ?Res |
|
| February 14, 2022 |
NEXI / NexImmune, Inc. / ArrowMark Colorado Holdings LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
NEXI / NexImmune, Inc. / Piedmont Capital Partners, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NexImmune, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 65344D109 (CUSIP Number) February 11, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 11, 2022 |
NEXI / NexImmune, Inc. / BARER SOL J - SC 13G Passive Investment Execution Version UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEXIMMUNE, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 11, 2022 |
NEXI / NexImmune, Inc. / B&S NexImmune Holdco LLC - SC 13G Passive Investment Execution Version UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NEXIMMUNE, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| December 13, 2021 |
NexImmune Announces Preliminary Phase 1/2 Exhibit 99.1 NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma ? Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition ? Phase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory multiple myeloma patients who have failed ?3 prior lines of therapy is ongoing GAITHERSBURG, MD |
|
| December 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2021 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-4004 |
|
| November 12, 2021 |
NEXIMMUNE, INC. BALANCE SHEETS Exhibit 99.1 NexImmune Reports Third Quarter 2021 Financial Results and Provides Business Updates ?Advancing two lead product candidates in Phase 1/2 clinical trials ?Additional clinical and preclinical data anticipated by year end 2021 and first half 2022 ?Announced collaboration with Yale University Department of Immunobiology to explore use of AIM INJ in regard to regulation of Type 1 Diabetes |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 9, 2021 |
Exhibit 99.1 NexImmune Reports Second Quarter 2021 Financial Results and Provides Business Updates ? Announcing first solid tumor indication in HPV associated-malignancies ? NEXI-003 ? Advancing two lead product candidates in Phase 1/2 clinical trials ? Additional clinical and preclinical data anticipated in the second half of 2021 GAITHERSBURG, Md., August 9, 2021 (GLOBE NEWSWIRE) - NexImmune, In |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40045 NEX |
|
| August 9, 2021 |
NexImmune to Explore the Use of AIMTM Direct Injection Technology in Type 1 Diabetes Exhibit 99.2 NexImmune to Explore the Use of AIMTM Direct Injection Technology in Type 1 Diabetes GAITHERSBURG, MD ? August 9, 2021 ? NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced a collaboration with Yale Un |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- NEXIMMUNE, INC. |
|
| May 17, 2021 |
Exhibit 99.1 NexImmune Reports First Quarter 2021 Financial Results and Recent Updates ? Advancing two lead product candidates in Phase 1/2 clinical trials ? Completed successful $126M initial public offering (IPO) in February 2021 ? Additional clinical and preclinical data anticipated in the second half of 2021 GAITHERSBURG, Md., May 17, 2021 (GLOBE NEWSWIRE) ? NexImmune, Inc. (Nasdaq: NEXI), a c |
|
| May 17, 2021 |
Non-Employee Director Compensation Policy Exhibit 10.10 NexImmune, Inc. Non-Employee Director Compensation Policy The Board of Directors of NexImmune, Inc. (the ?Company?) has approved the following Non-Employee Director Compensation Policy (this ?Policy?). The Policy is apply to all non-employee directors of the Company. In exchange for their service, each director will be eligible for the following annual cash compensation, cash compens |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 31, 2021 |
Exhibit 4.4 DESCRIPTION OF CAPITAL STOCK General Upon the completion of this offering, our authorized capital stock will consist of 250,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which will be undesignated. As of January 31, 2021, there were 1,274,474 shares of our common stock issued and outstanding. T |
|
| March 31, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. ) NEXIMMUNE, INC. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 65344D109 (CUSIP Number) February 17, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-400 |
|
| March 31, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 31, 2021 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned agree that the statement on Schedule 13G with respect to the Common stock, par value $0. |
|
| March 31, 2021 |
NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates Exhibit 99.1 NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates ? In 2020, advanced two product candidates into Phase 1/2 clinical trials while strengthening Board of Directors and management team ? Completed successful $126M initial public offering (IPO) in February 2021 to fund continuing operations through the second quarter of 2022 ? Additional clinical and preclinical dat |
|
| February 25, 2021 |
S-8 1 d149166ds8.htm S-8 As filed with the Securities and Exchange Commission on February 25, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 45-2518457 (State or other jurisdiction of incorporation or or |
|
| February 18, 2021 |
Amended and Restated Bylaws of the Registrant Exhibit 3.2 NEXIMMUNE, INC. AMENDED AND RESTATED BYLAWS (Effective as of February 17, 2021) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders of NexImmune, Inc. (the ?Corporation?), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such pl |
|
| February 18, 2021 |
Exhibit 99.1 NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares Gaithersburg, MD?February 17, 2021?NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body?s own T cells to generate a specific, potent and durable immune response, |
|
| February 18, 2021 |
Sixth Amended and Restated Certificate of Incorporation of the Registrant Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NexImmune, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with the Secretary of |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 001-40045 45-2518457 (State or other jurisdiction of incorporation) (Commission File |
|
| February 16, 2021 |
6,471,000 Shares NexImmune, Inc. Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-252220 Registration No. 333-253021 PROSPECTUS 6,471,000 Shares NexImmune, Inc. Common Stock This is an initial public offering of shares of the common stock of NexImmune, Inc. We are offering 6,471,000 shares of our common stock. No public market currently exists for our common stock. Our common stock has been approved for lis |
|
| February 11, 2021 |
S-1MEF As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. |
|
| February 11, 2021 |
Registration Statement on Form S-1, as amended S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 11, 2021 Registration No. |
|
| February 9, 2021 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NEXIMMUNE, INC. (Exact name of registrant as specified in its charter) Delaware 45-2518457 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No |
|
| February 9, 2021 |
CORRESP 1 filename1.htm NexImmune, Inc. 9119 Gaither Road Gaithersburg, MD 20877 February 9, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: NexImmune, Inc. Registration Statement on Form S-1 File No. 333-252220 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of the General |
|
| February 9, 2021 |
February 9, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Joe McCann Gary Newberry Kevin Kuhar Re: NexImmune, Inc. Registration Statement on Form S-1 (File No. 333-252220) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act |
|
| February 8, 2021 |
Form of Stock Option Agreement under the 2018 Equity Incentive Plan, as amended. EX-10.3.2 Exhibit 10.3.2 NEXIMMUNE, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2018 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: Incentive Stock Option Non-Qualified Stock Option 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Ve |
|
| February 8, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 8, 2021 Registration No. |
|
| February 8, 2021 |
Non-Employee Director Compensation Policy. EX-10.10 Exhibit 10.10 NexImmune, Inc. Non-Employee Director Compensation Policy The Board of Directors of NexImmune, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”) which establishes compensation to be paid to non-employee directors of the Company, effective as of the closing of the Company’s initial public offering of common stock (the “E |
|
| February 8, 2021 |
Form of Indemnification Agreement. EX-10.1 Exhibit 10.1 NEXIMMUNE, INC. INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this th day of , 20 , by and between NexImmune, Inc. a Delaware corporation (the “Company”), and (“Indemnitee”). WHEREAS, qualified persons are reluctant to serve corporations as directors or otherwise unless they are provided with broad indemnification and insu |
|
| February 8, 2021 |
2018 Equity Incentive Plan, as amended. EX-10.3.1 Exhibit 10.3.1 NEXIMMUNE, INC. 2018 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. (b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, (iv) Restric |
|
| February 8, 2021 |
Employment Agreement, by and between the Company and John Trainer, M.B.A., dated January 6, 2020. EX-10.6 Exhibit 10.6 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of this 6th day of January, 2020 (the “Effective Date”) by and between John Trainer (“Employee”) and Nexlmmune, Inc. (“Company”). WHEREAS, Company and Employee desire that Employee serve as the Company’s Chief Financial Officer; NOW THEREFORE, in consideration of the mutual promises set forth |
|
| February 8, 2021 |
Form of Stock Option Agreement under the 2017 Equity Incentive Plan, as amended. EX-10.2.2 Exhibit 10.2.2 NEXIMMUNE, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2017 Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: Incentive Stock Option Non-Qualified Stock Option 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Ve |
|
| February 8, 2021 |
2017 Equity Incentive Plan, as amended. EX-10.2.1 Exhibit 10.2.1 NEXIMMUNE, INC. 2017 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. (b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, (iv) Restric |
|
| February 8, 2021 |
Employment Agreement, by and between the Company and Scott Carmer, dated February 3, 2021. EX-10.5 Exhibit 10.5 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of February 3, 2021 (the “Effective Date”) by and between Scott Carmer (“Employee”) and NexImmune, Inc. (“Company”). WHEREAS, Employee currently serves as Company’s Chief Executive Officer and Company and Employee desire that Employee continue to serve in such capacity pursuant to the terms an |
|
| February 8, 2021 |
Employment Agreement, by and between the Company and Robert Knight, M.D., dated January 6, 2021. EX-10.9 Exhibit 10.9 NEXIMMUNE-KNIGHT EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of this 6th day of January, 2021 (the “Effective Date”) by and between Robert Knight, M.D., (“Employee”) and NexImmune, Inc. (“Company”). WHEREAS, Company and Employee desire that Employee serve as the Company’s Chief Medical Officer; NOW THEREFORE, in consideration of the mut |
|
| February 8, 2021 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NexImmune, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: The Certificate of Incorporation of the Corporation was filed with the Secret |
|
| February 8, 2021 |
EX-4.3 Exhibit 4.3 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of November, 2019 by and among NexImmune, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any A |
|
| February 8, 2021 |
EX-10.7 Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of this 4th day of January, 2021 (the “Effective Date”) by and between Jerome Zeldis, M.D., Ph.D. (“Employee”) and NexImmune, Inc. (“Company”). WHEREAS, Company and Employee desire that Employee serve as the Company’s Executive Vice President, Head of Research and Development; NOW THEREFORE, i |
|
| February 8, 2021 |
Certificate of Amendment to Restated Certificate of Incorporation of the Registrant. EX-3.1.3 Exhibit 3.1.3 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) NexImmune, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: 1. The name of the corporation (hereinafter called the “Corporation”) is NexImmune, In |
|
| February 8, 2021 |
Form of Underwriting Agreement. EX-1.1 Exhibit 1.1 [] Shares NexImmune, Inc. Common Stock UNDERWRITING AGREEMENT [], 2021 BARCLAYS CAPITAL INC. CANTOR FITZGERALD & CO. RAYMOND JAMES & ASSOCIATES, INC. As Representatives of the several Underwriters named in Schedule I c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 c/o Raymond James & Assoc |
|
| February 8, 2021 |
Employment Agreement, by and between the Registrant and Kristi Jones, dated February 27, 2017. EX-10.8 Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is entered into as of this 1st day of June, 2017 (the “Effective Date”) by and between Kristi Jones (“Employee”) and NexImmune, Inc. (“Company”). WHEREAS, Employee currently serves as Company’s Chief Business Officer, and Company and Employee desire that Employee continue to serve in such capacity pursuant to th |
|
| February 8, 2021 |
Form of Stock Option Agreement under the 2021 Equity Incentive Plan. EX-10.4.2 Exhibit 10.4.2 NEXIMMUNE, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, NexImmune, Inc., a Delaware corporation (the “Company”) has granted you an option under its 2021 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your Gra |
|
| February 8, 2021 |
Form of Common Stock Certificate. EX-4.1 Exhibit 4.1 Form of CommonStock Certificate 1234567 THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER AGENT AND REGISTRAR, FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF NexImmune, Inc. (hereinafter called the “Company”), transferable on the books of the Company in person or by duly authorized attorney, upon sur |
|
| February 8, 2021 |
Form of Convertible Promissory Note, as amended. EX-4.2 Exhibit 4.2 Execution Version THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECT |
|
| February 8, 2021 |
Form of Amended and Restated By-Laws (to be effective upon completion of this offering). EX-3.4 Exhibit 3.4 NEXIMMUNE, INC. AMENDED AND RESTATED BYLAWS (Effective as of February , 2021) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders of NexImmune, Inc. (the “Corporation”), for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at su |
|
| February 8, 2021 |
EX-10.4.1 Exhibit 10.4.1 NEXIMMUNE, INC. 2021 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. (b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, (iii) Restricted Stock Awards, (iv) Restric |
|
| January 19, 2021 |
EX-3.1.2 Exhibit 3.1.2 CERTIFICATE OF CORRECTION OF RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. It is hereby certified that: 1. The name of the corporation (hereinafter called the “Corporation”) is Neximmune, Inc. 2. The Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on June 7, 2011. Thereafter a Restated Certificate of I |
|
| January 19, 2021 |
EX-10.11 Exhibit 10.11 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY & NEXIMMUNE, INC. JHU Agreement: # - [***] CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltim |
|
| January 19, 2021 |
EX-10.12 6 d216127dex1012.htm EX-10.12 Exhibit 10.12 LEASE AGREEMENT THIS LEASE AGREEMENT, made this 30 day of June 2017, by and between W. M. RICKMAN CONSTRUCTION CO., LLC (“LANDLORD”) and NEXIMMUNE, INC. (“TENANT”). W I T N E S S E T H: 1. DEMISE OF PREMISES Landlord hereby demises unto Tenant, and Tenant hereby leases from Landlord for the terms and upon the conditions set forth in this Lease, |
|
| January 19, 2021 |
Exhibit 3.3 BYLAWS OF NEXIMMUNE, INC. (A DELAWARE CORPORATION) BYLAWS OF NEXIMMUNE, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware will be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation will also have and maintain an office or principal place of business at s |
|
| January 19, 2021 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on January 19, 2021 Registration No. |
|
| January 19, 2021 |
Fifth Amended and Restated Certificate of Incorporation of the Registrant. EX-3.1.1 Exhibit 3.1.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NexImmune, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That t |
|
| January 19, 2021 |
EX-10.13 Exhibit 10.13 SUBLEASE AGREEMENT THIS REVISED SUBLEASE is made and executed the 11th day of December, 2017 by and between Nexlmmune, Inc. (a Maryland corporation), (hereinafter called “Tenant”), and Modavar Pharmaceuticals LLC (a Delaware corporation) (hereinafter called “Subtenant”). W I T N E S S E T H WHEREAS, Tenant and W. M. Rickman Construction Co., LLC (hereinafter called “Landlord |
|
| January 15, 2021 |
EX-10.11 Exhibit 10.11 AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT BETWEEN THE JOHNS HOPKINS UNIVERSITY & NEXIMMUNE, INC. JHU Agreement: # - [***] CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltim |
|
| January 15, 2021 |
EX-10.12 Exhibit 10.12 LEASE AGREEMENT THIS LEASE AGREEMENT, made this 30 day of June 2017, by and between W. M. RICKMAN CONSTRUCTION CO., LLC (“LANDLORD”) and NEXIMMUNE, INC. (“TENANT”). W I T N E S S E T H: 1. DEMISE OF PREMISES Landlord hereby demises unto Tenant, and Tenant hereby leases from Landlord for the terms and upon the conditions set forth in this Lease, approximately 22,800 square fe |
|
| January 15, 2021 |
EX-10.13 Exhibit 10.13 SUBLEASE AGREEMENT THIS REVISED SUBLEASE is made and executed the 11th day of December, 2017 by and between Nexlmmune, Inc. (a Maryland corporation), (hereinafter called “Tenant”), and Modavar Pharmaceuticals LLC (a Delaware corporation) (hereinafter called “Subtenant”). W I T N E S S E T H WHEREAS, Tenant and W. M. Rickman Construction Co., LLC (hereinafter called “Landlord |
|
| January 15, 2021 |
One Financial Center Boston, MA 02111 617 542 6000 mintz.com Via Edgar January 15, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Joe McCann Gary Newberry Kevin Kuhar Re: NexImmune, Inc. Draft Registration Statement on Form S-1 Submitted December 14, 2020 CIK No. 0001538210 Dear |
|
| January 15, 2021 |
DRS/A Table of Contents As confidentially submitted to the Securities and Exchange Commission on January 15, 2021 pursuant to Section 6(e) of the Securities Act of 1933, as amended. |
|
| January 15, 2021 |
EX-3.1.1 Exhibit 3.1.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NexImmune, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That t |
|
| January 15, 2021 |
CERTIFICATE OF CORRECTION RESTATED CERTIFICATE OF INCORPORATION NEXIMMUNE, INC. EX-3.1.2 Exhibit 3.1.2 CERTIFICATE OF CORRECTION OF RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. It is hereby certified that: 1. The name of the corporation (hereinafter called the “Corporation”) is Neximmune, Inc. 2. The Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on June 7, 2011. Thereafter a Restated Certificate of I |
|
| January 15, 2021 |
BYLAWS NEXIMMUNE, INC. (A DELAWARE CORPORATION) EX-3.3 Exhibit 3.3 BYLAWS OF NEXIMMUNE, INC. (A DELAWARE CORPORATION) BYLAWS OF NEXIMMUNE, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware will be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation will also have and maintain an office or principal place of busine |
|
| December 14, 2020 |
Exhibit 3.1.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEXIMMUNE, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) NexImmune, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That the name o |
|
| December 14, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on December 11, 2020 pursuant to Section 6(e) of the Securities Act of 1933, as amended. |
|
| December 14, 2020 |
BYLAWS NEXIMMUNE, INC. (A DELAWARE CORPORATION) Exhibit 3.3 BYLAWS OF NEXIMMUNE, INC. (A DELAWARE CORPORATION) BYLAWS OF NEXIMMUNE, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware will be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation will also have and maintain an office or principal place of business at s |
